Positive Phase 2a data with clean safety profile and broad pathway activity de-risks EVO301's mechanism. Watch for Phase 2b initiation in mid-2027 and potential partnership interest given the differentiated IL-18 target.
Price Chart
Executive Summary
Evommune presented late-breaking Phase 2a proof-of-concept data for EVO301 in atopic dermatitis at the EADV 2026 Congress. The 70-patient trial met its primary endpoint with a 55% LS mean EASI reduction at Week 12 vs 22% for placebo (p<0.01), showing a favorable safety profile and broad anti-inflammatory biomarker activity. The company plans to initiate a subcutaneous Phase 2b dose-ranging trial in mid-2027.
Key Facts
- Phase 2a trial (n=70) met primary endpoint: 55% LS mean EASI reduction at Week 12 vs 22% placebo (p<0.01)
- Statistically significant separation from placebo observed as early as Week 4 (41% vs 18%) and maintained through Week 12
- EASI-50 at Week 12: 63% EVO301 vs 23% placebo; EASI-75: 29% vs 9%
- No treatment-related serious/severe adverse events, no discontinuations, no conjunctivitis
- Plan to initiate subcutaneous Phase 2b dose-ranging trial in mid-2027
- Biomarker data confirm Th2, Th1, Th17/22 pathway modulation
Financial Impact
No financial figures disclosed; positive clinical proof-of-concept for EVO301 in a large market (atopic dermatitis)
Risk Factors
- Phase 2b subcutaneous formulation may not replicate IV results
- Competition from approved AD biologics (Dupixent, Adbry, etc.)
- Clinical-stage company with no approved products or revenue
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-409865 |
| Document: evmn-ex99_1.htm | 0001193125-26-409865 |
| Document: 0001193125-26-409865-index-headers.html | 0001193125-26-409865 |
| Document: 0001193125-26-409865-index.html | 0001193125-26-409865 |
| Document: 0001193125-26-409865.txt | 0001193125-26-409865 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $7.21 | awaiting T+60 | — | $5.16 (−28.43%) |
Sep 15, 2026 6w ago | 8-K | $9.99 | awaiting T+60 | — | $5.16 (−48.35%) |
Jul 30, 2026 12w ago | 8-K | $11.35 $5.10 | ▼ −55.07% | ▼ −57.53% | $5.16 (−54.54%) |
Jul 10, 2026 15w ago | Insider Cluster | $12.10 $6.61 | ▼ −45.37% | ▼ −49.37% | $5.16 (−57.36%) |
Jun 29, 2026 17w ago | 8-K | $15.05 $9.60 | ▲ +36.21% | ▲ +40.60% | $5.16 (+65.71%) |
Jun 24, 2026 17w ago | Insider Cluster | $24.13 $9.65 | ▼ −60.01% | ▼ −63.74% | $5.16 (−78.62%) |
Jun 3, 2026 20w ago | Insider Cluster | $20.69 $13.23 | ▲ +36.06% | ▲ +37.94% | $5.16 (+75.06%) |
Jun 2, 2026 21w ago | 144 | $19.73 $13.48 | ▼ −31.68% | ▼ −34.18% | $5.16 (−73.85%) |
Jun 1, 2026 21w ago | Insider Cluster | $19.82 $14.11 | ▼ −28.81% | ▼ −29.93% | $5.16 (−73.97%) |
May 28, 2026 21w ago | 144 | $23.23 $13.67 | ▲ +41.15% | ▲ +42.34% | $5.16 (+77.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers